Subject :
At Sun Pharma, we are always keen to keep you ahead in knowledge updatation as well as in helping you to improve quality of clinical decision making. while achieving this objective we always undertake various surveys and studies to understand current clinical practices, perceptions about existing therapeutic options and also possible future challenges in the management of disease burden. The below survey is aimed to understand the same and the summary or outcome from the same will be used to build our in-clinic communication, future knowledge updation. program content and also to evaluate future therapeutic options. Your responses will be used at aggregate level.
Introduction
Extensive and robust evidence has established lowdensity lipoprotein cholesterol (LDL-C) as causal for atherosclerotic cardiovascular disease (ASCVD). Irrespective of therapeutic strategy, lowering LDL-C levels reduces the risk of ASCVD events, as demonstrated in major cardiovascular outcomes studies in very high-risk patients treated with a statin. The safety of these LDL-lowering therapies has also been demonstrated.
Despite this overwhelming body of evidence, controversy persists regarding the role of LDL-C as a cause of ASCVD. Frequent, non-evidence-based assertions published in the media suggest that statins are unsafe and that lowering LDL-C to very low levels is dangerous. There is also uncertainty regarding the veracity of adverse effects of statins, including statin associated muscle symptoms
The World Heart Federation has developed a series of 'roadmaps' which aim to reduce cardiovascular disease in developing world regions. One of these roadmaps has focused on identifying barriers to effective cholesterol management gaps in knowledge and practice .
There is little information, however, regarding the beliefs and behaviour of physicians responsible for managing patients with dyslipidaemia in their routine practice. These aimed to evaluate cultural differences among physicians in their beliefs and routine practice of managing dyslipidaemia.
|
}}){kind=logo}